bims-mesote Biomed News
on Mesothelioma
Issue of 2023–01–15
seven papers selected by
Laura Mannarino, Humanitas Research
  1. Asbestos-associated pulmonary disease.
  2. Case report: Rare intrapulmonary malignant mesothelioma complicated with myositis.
  3. Efficacy and safety of nivolumab with ipilimumab for recurrent malignant pleural mesothelioma after primary surgical intervention.
  4. Serum Extracellular Vesicle-Derived microRNAs as Potential Biomarkers for Pleural Mesothelioma in a European Prospective Study.
  5. Primary Peritoneal Mesothelioma: Diagnostic Challenges of This Lethal Imposter.
  6. Carbon-ion beam irradiation in combination with cisplatin effectively suppresses xenografted malignant pleural mesothelioma.
  7. Contemporary issues in the surgical management of pleural mesothelioma.
  1. Curr Opin Pulm Med. 2023 Jan 12.
    Asbestos-associated pulmonary disease.
    Jose Diego Caceres, Anand N Venkata.
       PURPOSE OF REVIEW: Exposure to asbestos can cause both benign and malignant, pulmonary and pleural diseases. In the current era of low asbestos exposure, it is critical to be aware of complications from asbestos exposure; as they often arise after decades of exposure, asbestos-related pulmonary complications include asbestosis, pleural plaques, diffuse pleural thickening, benign asbestos-related pleural effusions and malignant pleural mesothelioma.
    RECENT FINDINGS: Multiple recent studies are featured in this review, including a study evaluating imaging characteristics of asbestos with other fibrotic lung diseases, a study that quantified pleural plaques on computed tomography imaging and its impact on pulmonary function, a study that examined the risk of lung cancer with pleural plaques among two large cohorts and a review of nonasbestos causes of malignant mesothelioma.
    SUMMARY: Asbestos-related pulmonary and pleural diseases continue to cause significant morbidity and mortality. This review summarizes the current advances in this field and highlights areas that need additional research.
    DOI:  https://doi.org/10.1097/MCP.0000000000000939
  2. Front Oncol. 2022 ;12 1074821
    Case report: Rare intrapulmonary malignant mesothelioma complicated with myositis.
    Dandan Gong, Jian Yu, Xiaodong Jiang.
      Malignant pleural mesothelioma is an uncommon aggressive tumor. Its incidence is even lower when the lung parenchyma is the primary site. Myositis is a common paraneoplastic syndrome, but it rarely presents with malignant pleural mesothelioma. This report presents a rare intrapulmonary malignant mesothelioma complicated by cancer-associated myositis. The patient presented with limb muscle weakness as the first symptom and was diagnosed with intrapulmonary malignant mesothelioma complicated by cancer-associated myositis on the basis of clinical, histological, immunohistochemical, and radiological findings. The patient responded poorly to conventional hormone therapy and died of respiratory failure within 2 months after the first presence of limb muscle weakness.
    Keywords:  cancer-associated myositis; lung parenchyma; mesothelioma; oncology; primary
    DOI:  https://doi.org/10.3389/fonc.2022.1074821
  3. Int J Clin Oncol. 2023 Jan 07.
    Efficacy and safety of nivolumab with ipilimumab for recurrent malignant pleural mesothelioma after primary surgical intervention.
    Akifumi Nakamura, Masaki Hashimoto, Nobuyuki Kondo, Seiji Matsumoto, Ayumi Kuroda, Toshiyuki Minami, Kazuhiro Kitajima, Kozo Kuribayashi, Takashi Kijima, Seiki Hasegawa.
       BACKGROUND: Treatment of recurrent malignant pleural mesothelioma (MPM) remains challenging. Our study examined the efficacy, tolerability, and safety of nivolumab with ipilimumab treatment for recurrent MPM after primary curative-intent surgery.
    METHODS: Treatment comprised 360 mg nivolumab every 3 weeks and 1 mg/kg of ipilimumab every 6 weeks, both administered intravenously. Both were discontinued for progressive disease or serious adverse events (AEs). Additional post-treatment data were evaluated, including objective response rate (ORR), disease control rate (DCR), post-treatment survival, progression-free survival (PFS), and AEs. Tumor response was assessed using the modified Response Evaluation Criteria in Solid Tumors (RECIST 1.1). Survival analysis was estimated using a Kaplan-Meier plot. Feasibility analysis was performed using the National Cancer Institute Common Terminology Criteria for AEs version 5.0.
    RESULTS: Forty-one patients received nivolumab with ipilimumab for recurrent MPM after primary curative-intent surgery (median follow-up, 10.4 months; median treatment, 5.1 months). Overall, 18 patients exhibited partial response, 13 exhibited stable disease, and 10 had documented progressive disease. ORR and DCR were 43.9 and 75.6%, respectively. The 12-month post-treatment survival rate and PFS rate were 74.2 and 40.0%, respectively (median survival, not calculated; median PFS, 7.3 months). Further, 47 AEs were reported in 29 patients (70.7%), including grade 3-4 AEs in 14 patients (34.1%). Grade 4 hepatobiliary disorders were observed in 2 patients and grade 4 neutropenia was observed in 1.
    CONCLUSION: Nivolumab with ipilimumab treatment in patients with recurrent MPM after primary surgical treatment may be clinically efficacious, although serious AEs may be frequently observed.
    Keywords:  Adverse events; Anticytotoxic T lymphocyte antigen-4; Malignant pleural mesothelioma; Nivolumab plus ipilimumab; Postoperative recurrence; Programmed death-1 inhibition
    DOI:  https://doi.org/10.1007/s10147-023-02292-3
  4. Cancers (Basel). 2022 Dec 25. pii: 125. [Epub ahead of print]15(1):
    Serum Extracellular Vesicle-Derived microRNAs as Potential Biomarkers for Pleural Mesothelioma in a European Prospective Study.
    Elisabetta Casalone, Giovanni Birolo, Barbara Pardini, Alessandra Allione, Alessia Russo, Chiara Catalano, Manlio Mencoboni, Daniela Ferrante, Corrado Magnani, Marika Sculco, Irma Dianzani, Federica Grosso, Dario Mirabelli, Rosa Angela Filiberti, Ottavio Rena, Carlotta Sacerdote, Miguel Rodriguez-Barranco, Karl Smith-Byrne, Salvatore Panico, Claudia Agnoli, Theron Johnson, Rudolf Kaaks, Rosario Tumino, José María Huerta, Elio Riboli, Alicia K Heath, Camino Trobajo-Sanmartín, Matthias B Schulze, Calogero Saieva, Pilar Amiano, Antonio Agudo, Elisabete Weiderpass, Paolo Vineis, Giuseppe Matullo.
      Malignant pleural mesothelioma (MPM) is an aggressive cancer with a dismal prognosis. Early therapeutic interventions could improve patient outcomes. We aimed to identify a pattern of microRNAs (miRNAs) as potential early non-invasive markers of MPM. In a case-control study nested in the European Prospective Investigation into Cancer and Nutrition cohort, we screened the whole miRNome in serum extracellular vesicles (EVs) of preclinical MPM cases. In a subgroup of 20 preclinical samples collected five years prior MPM diagnosis, we observed an upregulation of miR-11400 (fold change (FC) = 2.6, adjusted p-value = 0.01), miR-148a-3p (FC = 1.5, p-value = 0.001), and miR-409-3p (FC = 1.5, p-value = 0.04) relative to matched controls. The 3-miRNA panel showed a good classification capacity with an area under the receiver operating characteristic curve (AUC) of 0.81 (specificity = 0.75, sensitivity = 0.70). The diagnostic ability of the model was also evaluated in an independent retrospective cohort, yielding a higher predictive power (AUC = 0.86). A signature of EV miRNA can be detected up to five years before MPM; moreover, the identified miRNAs could provide functional insights into the molecular changes related to the late carcinogenic process, preceding MPM development.
    Keywords:  biomarkers; early changes; malignant pleural mesothelioma; microRNAs; next generation sequencing
    DOI:  https://doi.org/10.3390/cancers15010125
  5. Case Rep Gastroenterol. 2022 Sep-Dec;16(3):16(3): 588-594
    Primary Peritoneal Mesothelioma: Diagnostic Challenges of This Lethal Imposter.
    Sonya K Dusseault, Okelue Edwards Okobi, Nimish Thakral, Vignesh Sankar, Ishan Gunawardene, Bryan Dawkins, Yaw Abu, Barry Davis.
      Primary Peritoneal Mesothelioma is a rapidly aggressive and rare neoplasm that arises from the lining of mesothelial cells of the peritoneum and spreads extensively within the confines of the abdominal cavity. The pathogenesis of all forms of mesothelioma is strongly associated with industrial pollutants, of which asbestos is the principal carcinogen. Characteristically, asbestos exposure has a strong relationship with mesothelioma of the pleura, but the peritoneal cavity is the second most commonly affected site. Additionally, in contrast to pleural mesothelioma, which has a male predominance (male-female ratio of between four and five to one), women comprise approximately one-half of all cases of malignant peritoneal mesothelioma. A thorough history of occupational/paraoccupational exposure along with histopathology is the key to timely diagnosis and treatment.
    Keywords:  Ascites; Case reports; Mesothelioma; Peritoneal carcinomatosis
    DOI:  https://doi.org/10.1159/000523935
  6. Am J Cancer Res. 2022 ;12(12): 5657-5667
    Carbon-ion beam irradiation in combination with cisplatin effectively suppresses xenografted malignant pleural mesothelioma.
    Sei Sai, Taiju Yamada, Keiko Ito, Nobuyuki Kanematsu, Masao Suzuki, Mitsuhiro Hayashi, Masashi Koto.
      Malignant pleural mesothelioma (MPM) is a rare aggressive cancer. This study investigated the growth-inhibitory effects of the combination of carbon ion beam irradiation (IR) and cisplatin (CDDP) on MPM xenografts. Carbon-ion beam IR at 15 Gy effectively inhibited tumor growth and decreased the tumor volume more than 90% after 9 weeks. However, tumor regrowth was observed after 17 weeks. The combination of carbon-ion beam IR (15 Gy) and CDDP significantly suppressed tumor growth after 9 weeks, with tumor regression being observed for more than 18 weeks. In contrast, X-ray IR (30 Gy) alone or in combination with CDDP effectively suppressed tumor growth and decreased the tumor volume after 11 weeks, but tumor growth was observed after 15 weeks. Carbon-ion beam IR at 25 Gy resulted in complete tumor regression without tumor regrowth in the 20-week follow-up period. Histopathological analysis revealed that combination of carbon-ion beam IR and CDDP exerted effective cytotoxic effects on MPM xenograft tumor cells and significantly promoted tumor cell necrosis, cavitation, and fibrosis when compared with individual treatment with carbon-ion beam, X-ray IR, or CDDP. Immunohistochemical analysis revealed that the expression levels of tumor cell migration and invasion-related proteins such as CXCL12, MMP2 and MMP9 were not significantly affected upon low dose (15 Gy) carbon-ion beam IR alone or in combination with CDDP but were markedly upregulated upon treatment with CDDP alone relative to control. However, IR with a high dose (25 Gy) carbon-ion beam inhibited tumor growth without upregulating these proteins. In conclusion, the combination of IR with a low dose (15 Gy) carbon ion beam and CDDP effectively suppressed MPM tumor in vivo without significantly upregulating CXCL12, MMP2 and MMP9, suggesting that combination therapy of carbon ion beam IR and chemotherapy is a promising therapeutic strategy for MPM.
    Keywords:  Carbon-ion irradiation; cisplatin; mesothelioma; tumor control
  7. J Surg Oncol. 2023 Feb;127(2): 343-354
    Contemporary issues in the surgical management of pleural mesothelioma.
    Juuso Paajanen, Michael T Jaklitsch, Raphael Bueno.
      The surgical management of pleural mesothelioma (PM) can be divided into diagnostic, staging, palliation, and cytoreductive surgery. In the cytoreductive surgical setting, the combination of different treatment modalities has led to better outcomes than surgery alone. The scarcity of high-quality studies has led to heterogeneity in management of PM across the mesothelioma treatment centers. Here, we review the literature regarding the most important open questions and ongoing clinical trials.
    Keywords:  mesothelioma; multimodality treatment; pleurectomy decortication; surgery
    DOI:  https://doi.org/10.1002/jso.27152
This page is being maintained by Thomas Krichel. It was last updated on 2024‒11‒22 at 4:20.